Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in CareDx, Inc (NASDAQ:CDNA)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of CareDx, Inc (NASDAQ:CDNAGet Rating) by 51.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 7,511 shares of the company’s stock after buying an additional 2,560 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in CareDx were worth $342,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of CDNA. Lindbrook Capital LLC increased its position in shares of CareDx by 2,183.9% during the fourth quarter. Lindbrook Capital LLC now owns 708 shares of the company’s stock worth $32,000 after acquiring an additional 677 shares during the period. Pinnacle Holdings LLC purchased a new position in shares of CareDx during the third quarter worth approximately $101,000. Dupont Capital Management Corp purchased a new position in shares of CareDx during the fourth quarter worth approximately $200,000. Cetera Advisor Networks LLC boosted its stake in shares of CareDx by 9.1% during the third quarter. Cetera Advisor Networks LLC now owns 3,610 shares of the company’s stock valued at $229,000 after purchasing an additional 300 shares in the last quarter. Finally, EFG Asset Management Americas Corp. boosted its stake in shares of CareDx by 33.7% during the fourth quarter. EFG Asset Management Americas Corp. now owns 5,619 shares of the company’s stock valued at $256,000 after purchasing an additional 1,415 shares in the last quarter.

Shares of CDNA opened at $30.57 on Friday. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -51.81 and a beta of 0.68. CareDx, Inc has a twelve month low of $27.87 and a twelve month high of $96.88. The company has a 50 day moving average of $36.58 and a two-hundred day moving average of $44.04.

CareDx (NASDAQ:CDNAGet Rating) last announced its earnings results on Thursday, February 24th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.12). The firm had revenue of $79.22 million during the quarter, compared to analyst estimates of $78.10 million. CareDx had a negative net margin of 10.35% and a negative return on equity of 6.49%. CareDx’s revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share. As a group, research analysts anticipate that CareDx, Inc will post -0.92 earnings per share for the current fiscal year.

In related news, insider Reginald Seeto sold 4,988 shares of the firm’s stock in a transaction on Friday, February 4th. The shares were sold at an average price of $40.34, for a total transaction of $201,215.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter Maag sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 5th. The stock was sold at an average price of $38.64, for a total transaction of $386,400.00. Following the transaction, the director now directly owns 311,689 shares of the company’s stock, valued at approximately $12,043,662.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 70,893 shares of company stock valued at $2,757,930. Corporate insiders own 4.60% of the company’s stock.

A number of equities analysts have recently issued reports on CDNA shares. Raymond James dropped their price objective on shares of CareDx from $90.00 to $52.00 and set a “strong-buy” rating on the stock in a research note on Friday, February 25th. Craig Hallum dropped their price objective on shares of CareDx from $106.00 to $87.00 in a research note on Friday, February 25th. Zacks Investment Research downgraded shares of CareDx from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 13th. StockNews.com downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research note on Friday, April 8th. Finally, BTIG Research dropped their price objective on shares of CareDx from $100.00 to $65.00 in a research note on Monday, February 28th. Two research analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, CareDx has an average rating of “Buy” and a consensus price target of $81.80.

About CareDx (Get Rating)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Featured Stories

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNAGet Rating).

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.